Showing results (121-130 of 130) with videos related to

Sort By:
Pageof 13
You have reached the last page of results.This site can display upto 130 results.
JCO Precision Oncology|September 11, 2020
<i>BRAF</i> in Lung Cancers: Analysis of Patient Cases Reveals Recurrent <i>BRAF</i> Mutations, Fusions, Kinase Duplications, and Concurrent AlterationsYuri Sheikine, Dean Pavlick, Samuel J Klempner, et al.
Cancer Cell|October 8, 2019
Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 ActivityJacqulyne P Robichaux, Yasir Y Elamin, R S K Vijayan, et al.
Nature|September 16, 2021
Structure-based classification predicts drug response in EGFR-mutant NSCLCJacqulyne P Robichaux, Xiuning Le, R S K Vijayan, et al.
The Oncologist|June 2, 2016
Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ HybridizationSiraj M Ali, Thomas Hensing, Alexa B Schrock, et al.
The Oncologist|October 13, 2019
The Pan-Cancer Landscape of Coamplification of the Tyrosine Kinases KIT, KDR, and PDGFRAUmut Disel, Russell Madison, Kumar Abhishek, et al.
The New England Journal of Medicine|June 23, 2021
Acquired Resistance to KRAS<sup>G12C</sup> Inhibition in CancerMark M Awad, Shengwu Liu, Igor I Rybkin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2021
Optimized EGFR Blockade Strategies in <i>EGFR</i> Addicted Gastroesophageal AdenocarcinomasSimona Corso, Filippo Pietrantonio, Maria Apicella, et al.
Cancer Discovery|April 2, 2024
Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET InhibitorsFederica Pecci, Seshiru Nakazawa, Biagio Ricciuti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 12, 2024
RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal CancerHarshabad Singh, Pranshu Sahgal, Kevin Kapner, et al.
Cancer Discovery|May 19, 2018
<i>STK11/LKB1</i> Mutations and PD-1 Inhibitor Resistance in <i>KRAS</i>-Mutant Lung AdenocarcinomaFerdinandos Skoulidis, Michael E Goldberg, Danielle M Greenawalt, et al.
Pageof 13